IndianapolisEli Lilly’s obesity-drug cousin now targets alcohol use disorder.
Three academic trials found semaglutide reduced craving and heavy drinking in people with alcohol use disorder.
Brenipatide mimics two gut hormones and stays active 9-12 days against 5-7 for approved GLP-1 drugs, Lilly data show.
Obesity specialist Randy Seeley says it is unclear that anything but the half-life sets it apart from marketed drugs.
Baseline Therapeutics plans a phase III trial of BT-001 for alcohol use disorder in early 2027.
How each outlet framed it
- Nature leans favorable
- frames GLP-1 brain-drug interest as a shift in pharma priorities, citing Lilly's brenipatide alcohol trial and Kariya's KP405 Parkinson's results
Sources: Nature